Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Metadata
Title
Risk factors for local recurrence after breast-conserving therapy
Authors
E. Shin
Yuichi Takatsuka
Yasuhiko Okamura
Tetsuro Kobayashi
Isamu Nishisho
Nobuteru Kikkawa
Kunimitsu Kawahara
Akihiko Kurata
Masatoshi Otani
Masashi Takeda
Publication date
01-08-1999
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 4/1999
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s101470050059

Other articles of this Issue 4/1999

International Journal of Clinical Oncology 4/1999 Go to the issue

OriginalPaper

Long-term follow-up in patients with bilateral testicular germ cell tumors: a report of ten cases

OriginalPaper

Antitumor effect of monoclonal antibody-carboplatin conjugates in nude mice bearing human ovarian cancer cells

CASE REPORT

Severe 5-fluorouracil-induced toxicity due to decreased dihydropyrimidine dehydrogenase activity: report of a patient survival and urinary pyrimidine and dihydropyrimidine levels

OriginalPaper

Mediastinal yolk sac tumor in a woman

OriginalPaper

Pulmonary adenocarcinoma metastatic to the gingiva

OriginalPaper

Quantitative evaluation of consistency of early invasive carcinoma of the tongue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits